# KLOW vs GLOW: How the Four-Peptide Blend Differs — the KLOW peptide vs GLOW | Clinic KLOW

> KLOW vs GLOW: how the four-peptide KLOW peptide blend differs from the three-peptide one. The short answer is KPV — the anti-inflammatory arm KLOW adds — explained plainly and cited.

Same three repair peptides, one extra arm. The whole difference is whether KPV is in the vial.

## The short version

If you only remember one thing about **KLOW vs GLOW**, make it this: KLOW is GLOW plus one more peptide. GLOW is a three-peptide research blend — GHK-Cu, BPC-157 and TB-500. KLOW is those same three plus KPV, a small anti-inflammatory peptide.

So the shared parts are identical: both carry the matrix arm (GHK-Cu), the repair-and-blood-supply arm (BPC-157), and the cell-migration arm (TB-500). The only difference is KLOW's fourth arm, KPV, which is studied for calming inflammation. That is the entire story in one line. Everything below just fills in what that extra arm does, and where the comparison runs out of real evidence — which is sooner than the marketing suggests, because neither blend has been tested as a blend in people.

## What KLOW adds that GLOW doesn't: KPV

KPV is the tripeptide Lys-Pro-Val, the C-terminal fragment (residues 11-13) of the hormone alpha-MSH. Its research role is anti-inflammatory: nanomolar KPV inhibits NF-kappaB and MAP-kinase inflammatory signaling and reduces pro-inflammatory cytokine secretion in epithelial and immune cells, and oral KPV reduced the severity of DSS- and TNBS-induced colitis in mice [3].

It also has a targeting trick. KPV is carried into cells by PepT1 (a di/tripeptide transporter), which is upregulated in inflamed gut tissue and immune cells [3] — so the anti-inflammatory effect tends to concentrate where inflammation already is. Mechanistically, KPV's action appears distinct from its parent peptides and is thought to work by inhibiting IL-1beta function [20]. That single added arm is the whole of what KLOW carries beyond GLOW.

## What the two blends share

Strip away KPV and KLOW and GLOW are the same three peptides doing the same three jobs. GHK-Cu is the matrix-and-collagen arm — it drives collagen and proteoglycan synthesis and modulates a broad set of repair genes [4][5], and it is the mass-dominant component in both blends. BPC-157 is the angiogenesis-and-connective-tissue arm — it activates VEGFR2 signaling [17] and accelerated cut-tendon healing in rats [2]. TB-500 is the cell-migration arm — thymosin beta-4 sped wound re-epithelialization by 42% at four days in rats [1].

So a reader comparing the two is really comparing "repair blend" versus "repair blend with an inflammation-control layer added." Both are research-only and unapproved; both contain the WADA-prohibited TB-500 arm.

## Does the extra arm make KLOW better?

Honestly: that cannot be answered from the literature. There is no head-to-head study of KLOW against GLOW, and neither blend has controlled human data. Some community reports describe KLOW as feeling "more anti-inflammatory" than the KPV-free GLOW blend — but that is a subjective impression from research-use forums, clearly anecdotal and not a measured outcome.

What can be said is narrower and fairer: KLOW adds a peptide whose own research is about reducing inflammation. Whether that translates into a better real-world result for any goal is untested, because the blends themselves are untested. The same pharmacokinetic mismatch applies to both — small tripeptides clear faster than BPC-157, whose half-life ran under about 30 minutes in formal study [18], so no single vial holds every arm at matched exposure. The community-reported effects, labeled anecdotal, are on [reported effects and safety](/effects).

---

A warm, plain-English reading desk for the four-peptide KLOW research record — KPV, GHK-Cu, BPC-157 and TB-500 read one honest arm at a time, every claim walked back to its study and the empty space where the blend trial should be left in plain sight; no clinic behind the desk and nothing here dosed, dispensed, or sold.